Chester County News and Community Website
EXTON, PA — Bentley Acceleration Initiatives recently announced the availability of OpenTower® iQ, a digital twin solution “powered by iTwin” for telecom towers that provides 3D visualization, real-time decision support, and …
Read MoreWASHINGTON, D.C. — The U.S. Department of Energy (DOE) has released its Hydrogen Program Plan to provide a strategic framework for the Department’s hydrogen research, development, and demonstration (RD&D) activities.
Read More
MASON CITY, IA — U.S. Secretary of Agriculture Sonny Perdue announced that the U.S. Department of Agriculture (USDA) has invested $22 million out of the up to $100 million in …
Read More
HARRISBURG, PA — The Pennsylvania Department of Transportation (PennDOT) announced recent achievements reflecting leadership in the realm of Highly Automated Vehicles (HAV) in Pennsylvania and the nation.
Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read More
WASHINGTON, D.C. — The U.S. Department of Energy (DOE) recently announced $100 million in funding over five years for two new awards focused on advancing artificial photosynthesis for the production …
Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read More
CHICAGO, IL — At a recent press conference at the University of Chicago, the U.S. Department of Energy (DOE) unveiled a report that lays out a blueprint strategy for the …
Read More
WASHINGTON, D.C. — The U.S. Department of Energy (DOE) announced $118 million in federal funding to support the Coal FIRST (Flexible, Innovative, Resilient, Small, Transformative) Initiative. Under this cost-shared research …
Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today announced the decision to discontinue the …
Read More